Stock Upgrades Today Worth Watching for Active Traders

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  22 Oct 2025
 

•   APGE  
   
  0.00%
•   CRMD  
   
  0.00%
•   DCTH  
   
  0.00%
•   DKNG  
   
  0.00%
•   FLUT  
   
  0.00%

$MGTX absolutely dominates today's upgrade list with Raymond James initiating Strong Buy coverage and projecting a staggering 200.92% upside potential. MeiraGTx Holdings operates in gene therapy, developing treatments for ocular and neurodegenerative diseases. Raymond James initiating with such an extraordinary target suggests they see the clinical pipeline addressing massive unmet medical needs and believe the current valuation dramatically underprices the commercial opportunity. For biotech traders willing to accept clinical-stage risks, this represents one of the most bullish calls in recent memory.

$DCTH received maintained Buy coverage from Canaccord Genuity with 121.42% upside forecast. Delcath Systems developed a proprietary chemotherapy delivery system for liver cancer that delivers high doses directly to the liver while minimizing systemic exposure. The triple-digit upside suggests Canaccord sees the technology as a potential game-changer in oncology, addressing significant unmet needs in liver cancer treatment.

$CRMD maintained Outperform from RBC Capital with 79.56% upside potential. CorMedix is advancing therapies to prevent catheter-related bloodstream infections affecting dialysis patients. The nearly 80% upside reflects RBC Capital's conviction that regulatory progress and commercialization milestones will substantially revalue the company as it addresses critical medical needs with significant healthcare cost implications.

$APGE received Outperform initiation from Mizuho with 71% upside potential. Apogee Therapeutics develops treatments for atopic dermatitis and chronic obstructive pulmonary disease. Mizuho's aggressive initiation indicates they believe the clinical programs target large patient populations with differentiated mechanisms potentially offering advantages over existing therapies in development.

$SFM maintained Outperform from Evercore ISI Group with 71.50% upside potential. Sprouts Farmers Market operates specialty grocery stores focusing on natural and organic products. Unlike the biotech names, Sprouts operates a proven business model with existing profitability, making the aggressive upside forecast particularly noteworthy. Evercore believes the specialty grocery segment will continue taking share from traditional grocers through expansion and comparable store sales growth.

$DKNG maintained Buy from Truist Securities with 65.80% upside potential. DraftKings operates in rapidly expanding online sports betting, benefiting from continued state legalization and growing consumer adoption. The substantial upside reflects Truist's conviction that market-leading position and improving unit economics will drive significant value as the online gaming market remains in early adoption stages.

$IDYA maintained Outperform from RBC Capital with 58.56% upside potential. IDEAYA Biosciences develops precision medicine therapies for cancer using synthetic lethality approaches. The maintained coverage with aggressive upside indicates RBC sees clinical validation approaching and believes the targeted approach to previously difficult cancers will drive substantial value creation.

$VRDN maintained Outperform from Oppenheimer with 57.62% upside potential. Viridian Therapeutics develops therapies for thyroid eye disease. The substantial upside suggests Oppenheimer sees significant commercial potential for clinical programs addressing a rare disease with limited treatment options and believes the market undervalues this opportunity.

$HUT maintained Market Outperform from JMP Securities with 54.58% downside indicated. Hut 8 operates cryptocurrency mining and digital infrastructure. Despite the negative near-term forecast, JMP maintains Outperform coverage, suggesting they believe long-term infrastructure value remains intact even as crypto volatility creates near-term pricing pressure.

$MGM maintained Buy from Truist Securities with 49.51% upside potential. MGM Resorts International operates casino resorts and online gaming platforms. The aggressive upside reflects confidence in post-pandemic recovery continuing and online gaming expansion driving growth, with Truist seeing the market undervaluing MGM's diversified gaming assets.

$SN maintained Outperform from Oppenheimer with 48.09% upside potential. SharkNinja manufactures innovative home appliances and cleaning products. The aggressive upside suggests Oppenheimer sees product innovation pipeline continuing to drive market share gains despite headwinds facing consumer durables broadly.

$RVMD received Outperform initiation from Mizuho with 44.42% upside potential. Revolution Medicines develops targeted oncology therapies, particularly RAS inhibitors for cancer treatment. Mizuho's bullish initiation suggests analysts believe clinical programs addressing previously undruggable targets could drive substantial value in precision oncology.

$FLUT maintained Buy from Truist Securities with 38.92% upside potential. Flutter Entertainment operates online sports betting and gaming platforms globally. The maintained coverage indicates analysts see continued market share gains and regulatory expansion driving growth, with substantial upside suggesting Truist believes the market undervalues Flutter's dominant positions.

View All Headlines